Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
← catalyst calendarSponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
158actual
Sites
29
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-17 | actual | When the study began enrolling |
| Primary completion | Jul 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Seizures
Intervention
- Drug: Epidiolex — also filed as Cannabidiol, Epidyolex
Primary outcome
what the primary-completion date above is the date OFRetention Rate Percentage After Initiation of Treatment With Epidyolex
measured Up to 24 months post-dose.
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed